Home > > > Report Detail

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Name :
Date: 29-Jul-2022
No. of pages: 105
Inquire Before Buying

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Drugs In Development, 2022, provides an overview of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C (Genetic Disorders) pipeline landscape.

Niemann-Pick C disease is one of a group of lysosomal storage diseases that affect metabolism and that are caused by genetic mutations. It involves the accumulation of sphingolipids in cells throughout the body, particularly reticuloendothelial cells (the mononuclear phagocyte system). Symptoms include enlarged liver, brain damage, difficulty walking and swallowing, increased sensitivity to touch, difficulty speaking, loss of muscle tone, learning difficulties.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 2, 14, 5 and 1 respectively. Similarly, the Universities portfolio in Phase 0, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C (Genetic Disorders).

- The pipeline guide reviews pipeline therapeutics for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C (Genetic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C (Genetic Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Overview
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Companies Involved in Therapeutics Development
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Drug Profiles
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Dormant Projects
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Product Development Milestones
Featured News & Press Releases
Jul 13, 2022: Cyclo Therapeutics to present at the World Orphan Drug Congress USA 2022
Jun 24, 2022: Cyclo Therapeutics to present at the 2022 NPC Patient and Family Conference hosted by the Australian NPC Disease Foundation
May 09, 2022: Cyclo Therapeutics to participate in the virtual investor Niemann-Pick Disease Type C spotlight event
Mar 24, 2022: Azafaros announces FDA Grant of Orphan Drug Designation for AZ-3102 in the treatment of Niemann-Pick Disease
Feb 14, 2022: Azafaros presents positive clinical and preclinical data supporting development of lead compound AZ-3102 in lysosomal storage disorders at the 18th Annual WORLDSymposium conference
Feb 09, 2022: Cyclo therapeutics selected to present overview of pivotal phase 3 study for lead candidate, Trappsol Cyclo, at WORLDSymposium 2022
Feb 03, 2022: Cyclo Therapeutics announces formation of global steering committee comprised of leading experts to Advise on the global phase 3 clinical development program for Trappsol Cyclo in Niemann-Pick Disease Type C
Oct 18, 2021: Cyclo Therapeutics announces abstract accepted for poster presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM)
Oct 06, 2021: Cyclo Therapeutics to participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab
Jul 30, 2021: Cyclo Therapeutics announces new positive safety and efficacy data from ongoing phase 1 open-label extension study of Trappsol Cyclo for the treatment of Niemann-Pick disease type C1
Jul 27, 2021: Cyclo Therapeutics commences commercial-scale manufacturing for Trappsol Cyclo
Jun 21, 2021: Cyclo Therapeutics to present at the 2021 NPC patient and family conference hosted by the Australian NPC Disease Foundation
Jun 18, 2021: Cyclo Therapeutics starts enrolment in Phase III NPC1 treatment trial
Apr 27, 2021: Cyclo Therapeutics announces design of pivotal phase 3 study evaluating Trappsol Cyclo in Niemann-Pick Type C1
Mar 25, 2021: Cyclo Therapeutics meets primary efficacy endpoint in phase 1/2 trial from intravenous Trappsol Cyclo in rare disease Niemann-Pick Type C1 (NPC1)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Dormant Projects, 2022

List of Figures
Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
  • Global Cytokine Inhibitor Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Cytokine Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The development prospects of cytokine inhibitors are very broad, and these drugs have many medical applications and researches. Cytokine inhibitors can reduce The activity of cytokines, thereby inhibiting their role in immune responses and reducing The activation of immune cells and The occurrence o......
  • Global Microbial Growth Media Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    Microbial Growth Media is a nutrient component required by microorganisms, containing a variety of trace elements and trace elements, such as copper, iron, zinc, cobalt, manganese, etc. The global Microbial Growth Media market was valued at US$ 8007 million in 2023 and is anticipated to reach US$ 11530 million by 2030, witnessing a CAGR of 5.3% during The forecast period 2024-2030. The market for microbial growth media is essential in microbiology and biotechnology rese......
  • Global Protein Biochip Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 92
    Protein Biochip is a small Protein array used to quickly detect a large number of unknown proteins. It works in a similar way to a DNA chip. First, a large number of known proteins (such as monoclonal antibodies) are placed on a small substrate and then exposed to and reacted with The unknown protein sample. Due to The specific binding between The antigen and The antibody, it can finally be detected by means of laser. The global Protein Biochip market was valued at US$ 145 million i......
  • Global Isothermal Nucleic Acid Amplification Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 103
    Isothermal nucleic acid amplification is referred to isothermal nucleic acid amplification technology. And in this report, we get The statistics on reagents used in isothermal nucleic acid amplification technology. Nucleic acid isothermal amplification is a newer technique that amplifies DNA or RNA specific fragment from few copies to billion-fold copies under a one temperature condition, unlike PCR amplification that needs at least 30-35 thermal cycles to accomplish The reaction. T......
  • Global Microfluidics Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 134
    According to our LPI (LP Information) latest study, the global Microfluidics market size was valued at US$ 3118.7 million in 2023. With growing demand in downstream market, the Microfluidics is forecast to a readjusted size of US$ 7707.1 million by 2030 with a CAGR of 13.8% during review period. The research report highlights the growth potential of the global Microfluidics market. Microfluidics are expected to show stable growth in the future market. However, product differentiation, re......
  • Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 122
    According to our LPI (LP Information) latest study, the global Isothermal Nucleic Acid Amplification Technology (INAAT) market size was valued at US$ 6141.3 million in 2023. With growing demand in downstream market, the Isothermal Nucleic Acid Amplification Technology (INAAT) is forecast to a readjusted size of US$ 11250 million by 2030 with a CAGR of 9.0% during review period. The research report highlights the growth potential of the global Isothermal Nucleic Acid Amplification Technol......
  • Global Cytokines Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 119
    According to our LPI (LP Information) latest study, the global Cytokines market size was valued at US$ 203730 million in 2023. With growing demand in downstream market, the Cytokines is forecast to a readjusted size of US$ 611910 million by 2030 with a CAGR of 17.0% during review period. The research report highlights the growth potential of the global Cytokines market. Cytokines are expected to show stable growth in the future market. However, product differentiation, reducing costs, an......
  • Global Western Blot Imagers Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 94
    According to our LPI (LP Information) latest study, the global Western Blot Imagers market size was valued at US$ 406 million in 2023. With growing demand in downstream market, the Western Blot Imagers is forecast to a readjusted size of US$ 578.4 million by 2030 with a CAGR of 5.2% during review period. The research report highlights the growth potential of the global Western Blot Imagers market. Western Blot Imagers are expected to show stable growth in the future market. However, prod......
  • Global Procalcitonin Antibody Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 125
    According to our LPI (LP Information) latest study, the global Procalcitonin Antibody market size was valued at US$ million in 2023. With growing demand in downstream market, the Procalcitonin Antibody is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Procalcitonin Antibody market. Procalcitonin Antibody are expected to show stable growth in the future market. However, product di......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs